{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI+Protocol", "query": { "intervention": "FOLFIRI Protocol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 69, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FOLFIRI+Protocol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T10:48:07.136Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01133990", "title": "FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFIRI", "type": "DRUG" }, { "name": "E7820", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2010-03-04", "completion_date": "2011-02-18", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 6, "location_summary": "Denver, Colorado • Berkeley Heights, New Jersey • Mount Holly, New Jersey + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Berkeley Heights", "state": "New Jersey" }, { "city": "Mount Holly", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133990" }, { "nct_id": "NCT04929223", "title": "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "SY-5609", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FoundationOne®Liquid CDx", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 542, "start_date": "2021-10-22", "completion_date": "2030-08-31", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929223" }, { "nct_id": "NCT03035253", "title": "A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "OMP-305B83", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 16, "start_date": "2016-12", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 6, "location_summary": "Duarte, California • Denver, Colorado • Fort Collins, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035253" }, { "nct_id": "NCT06792695", "title": "A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 80, "start_date": "2025-03-12", "completion_date": "2028-09-29", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06792695" }, { "nct_id": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Histiocytic Neoplasm", "Histiocytosis", "BRAF Gene Mutation", "BRAF V600E", "BRAF V600 Mutation", "BRAF Mutation-Related Tumors", "BRAF", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Cancer", "Recurrent Lung Cancer", "Recurrent Lung Non-Small Cell Carcinoma", "NSCLC", "Solid Tumor", "Solid Carcinoma", "KRAS G12D", "KRAS G12V", "KRAS Mutation-Related Tumors", "NRAS Gene Mutation", "Thyroid Cancer", "Thyroid Carcinoma", "Colorectal Cancer", "Colorectal Carcinoma", "Recurrent Histiocytic and Dendritic Cell Neoplasm", "Brain Metastases", "Recurrent NSCLC", "KRAS G13C", "Acquired Resistance to KRAS G12C Inhibitor", "KRAS G12A", "KRAS G12F", "KRAS G12R", "KRAS G13D" ], "interventions": [ { "name": "S241656", "type": "DRUG" }, { "name": "FOLFOX6/FOLFOX7", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 554, "start_date": "2023-04-18", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05786924" }, { "nct_id": "NCT01896869", "title": "FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Vaccine", "type": "BIOLOGICAL" }, { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2013-11", "completion_date": "2019-05-03", "has_results": true, "last_update_posted_date": "2020-05-19", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 3, "location_summary": "San Francisco, California • Baltimore, Maryland • St Louis, Missouri", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896869" }, { "nct_id": "NCT03829410", "title": "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "KRAS Gene Mutation" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Cardiff Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2019-06-24", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2025-03-04", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829410" }, { "nct_id": "NCT01571284", "title": "Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "AFLIBERCEPT AVE0005", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 781, "start_date": "2012-05-30", "completion_date": "2017-01-31", "has_results": true, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 12, "location_summary": "Muscle Shoals, Alabama • Corona, California • Fountain Valley, California + 9 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01571284" }, { "nct_id": "NCT03798626", "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastroesophageal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Gevokizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 167, "start_date": "2019-05-22", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 3, "location_summary": "Los Angeles, California • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798626" }, { "nct_id": "NCT06840886", "title": "A Study of PHST001 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Ovarian Cancer", "Endometrial Cancer", "Cholangiocarcinoma", "CNS Tumor" ], "interventions": [ { "name": "PHST001", "type": "BIOLOGICAL" }, { "name": "Chemotherapy per Standard of Care", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pheast Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2025-03-31", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-02T10:48:07.136Z", "location_count": 20, "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06840886" } ] }